BeStock  
Stocks › Biotechnology › TBPH

Theravance Biopharma(Delisted) TBPH

US equityMarket cap rank #3323Biotechnology
$17.03 +$0.00 (0.00%)
Market closed · Oct 8, 12:00 am ET
Open$0.00
Prev close$17.03
Day range$0.00 – $0.00
Volume0.00
Market cap$884.18M
P/E (TTM)16.4
Dividend yield–

TBPH Stock News

Headlines matching Theravance Biopharma(Delisted) or the TBPH ticker, most recent first.

  • Theravance Biopharma(Delisted): Theravance Biopharma, Inc. - Cash Settlement/Acceleration of Expirations Option Symbol: TBPHOCC · 24 Sep 2026 · Direct mention
  • Theravance Biopharma(Delisted): Theravance Biopharma, Inc.- Broker-To-Broker Settlement/Exercise Considerations Option Symbol: TBPHOCC · 24 Sep 2026 · Direct mention
  • Theravance Biopharma: Theravance Biopharma, Inc. - Anticipated Cash Settlement Option Symbol: TBPHOCC · 29 Aug 2026 · Direct mention
  • Analysts' Opinions Are Mixed on These Healthcare Stocks: Rocket Pharmaceuticals (RCKT), Fractyl Health, Inc. (GUTS) and Theravance Biopharma (TBPH)TipRanks · 11 Aug 2026 · Direct mention
  • H.C. Wainwright Maintains Theravance Biopharma(TBPH.US) With Hold Rating, Maintains Target Price $17Market news · 11 Aug 2026 · Direct mention
  • H.C. Wainwright Downgrades Theravance Biopharma(TBPH.US) to Hold Rating, Raises Target Price to $17 MixedMarket news · 7 Jul 2026 · Direct mention
  • Theravance Biopharma(TBPH.US) 10% Shareholder Sells US$5.79 Million in Common StockMarket news · 2 Jul 2026 · Direct mention
  • BTIG Downgrades Theravance Biopharma(TBPH.US) to Hold Rating NegativeMarket news · 29 Jun 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Theravance Biopharma (TBPH)TipRanks · 29 Jun 2026 · Direct mention
  • BTIG Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $21Market news · 8 May 2026 · Direct mention
  • JonesTrading Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Raises Target Price to $19 PositiveMarket news · 28 May 2026 · Direct mention
  • B. Riley Securities Maintains Theravance Biopharma(TBPH.US) With Hold Rating, Raises Target Price to $17 PositiveMarket news · 7 Apr 2026 · Direct mention
  • Oppenheimer Downgrades Theravance Biopharma(TBPH.US) to Hold Rating, Cuts Target Price to $13.67 NegativeMarket news · 6 Mar 2026 · Direct mention
  • JonesTrading Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Cuts Target Price to $17 NegativeMarket news · 5 Mar 2026 · Direct mention
  • H.C. Wainwright Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Cuts Target Price to $15 NegativeMarket news · 5 Mar 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on TBPH.

Leave a comment

Scroll to Top